Participated · Equity · Jun 2025

Signify Bio is a Dallas, TX–based biotechnology company focused on improving development of in situ protein therapeutics by harnessing the human body’s natural protein-production capabilities. It combines signal peptide‑engineered control with mRNA‑encoded design to enable precise and rapid development of personalized medicines. The company’s SEND platform and iPhos lipid nanoparticles are designed to enable targeted, localized delivery of therapeutic proteins across multiple disease areas. Signify positions its approach to address unmet needs by delivering protein therapeutics directly where needed. Its management team includes co‑founders and senior scientists from UT Southwestern and industry veterans from Pfizer, Intellia and other organizations. The company intends to use the funds from the financing to expand operations and accelerate R&D efforts.

Participated · Series C · May 2025

CellCentric is a privately held, clinical-stage biotech company developing inobrodib, an orally bioavailable p300/CBP inhibitor. The lead program is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, and the company is enrolling a Phase 2 DOMMINO-1 study in the UK and US. CellCentric plans to initiate the global Phase 3 DOMMINO-2 trial in the second half of 2026. The company holds an IP portfolio and has clinical collaborations and strategic partnerships that provide external validation. Led by CEO Will West, CellCentric is based in Cambridge, UK, and maintains an additional office in Boston, MA. The article did not disclose revenue or other operating metrics.

Participated · Series B · May 2025

Alpheus Medical develops a proprietary sonodynamic therapy platform that pairs Low‑Intensity Diffuse Ultrasound (LIDU™) with oral 5‑ALA, a tumor‑selective sensitizer, to deliver non‑thermal, tumor‑targeted treatment. The therapy is designed to be performed in an outpatient setting and to selectively destroy cancer cells across a brain hemisphere without the need for imaging or sedation. Early results from two studies in newly diagnosed and recurrent glioblastoma patients have shown promise. The company collaborates with global neuro‑oncology leaders and is supported by healthcare investors and nonprofit venture vehicles focused on cancer. Recent financing will fund a randomized Phase 2B controlled trial evaluating SDT’s efficacy in newly diagnosed glioblastoma. Alpheus is based in Chanhassen, Minnesota. Alpheus Medical is developing a non-invasive sonodynamic therapy (SDT) drug-device combination that uses a sonosensitizer activated by low-intensity ultrasound to selectively kill cancer cells. The lead product is designed for outpatient, repeatable whole-hemisphere treatment of recurrent high-grade gliomas, including rGBM, and eliminates the requirement for concomitant imaging. The therapy aims to address the heterogeneous and diffuse nature of glioblastoma by treating both the primary tumor site and diseased tissue throughout the hemisphere. The company reports the therapy is in early clinical stage use and is not yet commercially available. Alpheus has support from the American Cancer Society and the National Brain Tumor Society and is based in Oakdale, Minn. The recently closed financing will be used to advance a multi-site first-in-human trial evaluating safety, feasibility, and molecular and clinical effects.

Participated · Seed · Feb 2025

Cerula Care delivers a team-based, cancer-specific behavioral health and care navigation platform that integrates directly with oncology practices. The company operates a virtual-first model offering counseling, health coaching, and psycho-oncology to improve quality of life for people undergoing cancer treatment. Cerula launched in 2024 with three large oncology practices and has reported statistically significant improvements in somatic symptoms, quality of life, anxiety, and depression within three months of care. Those clinical gains have translated into greater adherence to cancer care plans and a decrease in unwanted hospitalizations. The company raised an oversubscribed $3.7 million Seed round to scale operations. Cerula plans to use the new funding to expand services to more practices and invest in patient-facing technology.

Participated · Equity · Nov 2024

TailorMed provides an enterprise platform that manages the full lifecycle of patient support programs to reduce cost barriers and improve medication access and adherence. The company has built the nation’s largest Affordability Network, deployed across more than 800 hospitals, 1,300 clinics, and 650 pharmacies. TailorMed integrates directly with manufacturer assistance programs to automate patient support and streamline stakeholder workflows. Having reached an inflection point in its network evolution, the company is expanding into an end-to-end platform to tackle cost, access, and adherence across the medication continuum. The new financing will fund that expansion and broader efforts to create a seamless flow of data and resources across patients, providers, pharmacies, life sciences, and payers. TailorMed frames this work as addressing affordability at the point a prescription is written or dispensed to prevent delayed or skipped treatments. TailorMed Medical provides a technology platform that automates identification of financially at-risk patients and matches and enrolls them in financial resources such as co-pay assistance, replacement drug programs, government subsidies, community and state resources, disease-specific foundations, and programs addressing living expenses. Its platform is designed to reduce out-of-pocket responsibility for patients, helping to eliminate downstream financial hardship and avoidance of care. For health organizations, TailorMed shifts financial assistance from reactive matching or downstream collections to a proactive, point-of-care approach. The company serves physician practices, specialty clinics and health systems, and in 2021 expanded adoption into pharmacies nationwide. TailorMed said it will use the new funding to further expand its reach across health care with innovative financial solutions. Srulik Dvorsky is CEO and co-founder and the company is based in New York City.